Online, United States
Lectures & Conferences
The inaugural GPCRs - Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway, leveraging new structural and genetic data as well as, emerging screening tools and technologies and up and coming modalities.
Discover data driven case studies that showcase the challenges, learnings and takeaways currently being faced by large pharma, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology, age-related diseases and beyond.
Whether you are looking to harness the power of structural biology tools or emerging technologies, join fellow directors, heads and VPs of drug discovery, structural biology, and pharmacology at the GPCRs - Targeted Drug Discovery Summit - the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs.
Conference Only - Drug Developer: USD 2099.0,
Conference + Focus Day - Drug Developer: USD 2997.0,
Conference + Focus Day - Standard Pricing: USD 3697.0,
Conference Only - Standard Pricing: USD 2599.0,
Conference + Focus Day - Academic and Research Institute: USD 2597.0,
Conference Only - Academic and Research Institute: USD 1899.0
Speakers: Christel Menet, CSO, Confo Therapeutics, Christian Cortis, COO, Tectonic Therapeutic, Graeme Milligan, Professor of Biochemistry, University of Glasgow, Michael Hanson, CTO, ShouTi, Francis Willard, Research Advisor, Eli Lilly, Peter McNamara, SVP and Head of Research, Tectonic Therapeutic, Stacey Southall, Director - Biophysics / Cryo-EM, Sosei Heptares, Uli Stilz, VP, Novo Nordisk Bio Innovation Hub, Josephine Cardarelli, CSO, GPCR Therapeutics, Monica Schwartz, Director, Abalone Bio, Stuart Hughes, CEO, Pathios Therapeutics, Xavier Leroy, CSO, Domain Therapeutics, Brett Tounge, Co-Founder, Mebias Discovery, Leon Chan, Head of Biology, Octant, Naomi Handly, Head of Platform, Octant, Stuart Maudsley, Odysseus Professor of Receptor Pharmacology and Vice Chair and Co-Founder, University of Antwerp and heptOME, Barbara Cipriani, Head of Biology, Pathios Therapeutics, John McCorvy, Assistant Professor, Medical College of Wisconsin, Juan Jose Fung, Principal Scientist, GPCR Therapeutics, Robin Loving, CSO, Salipro Biotech, Gregory Tall, Associate Professor, University of Michigan Medical School, Irina Tikhonova, Reader, Queen's University Belfast, Oliver Hartley, VP - Drug Discovery, Orion Biotechnology, Scott Prosser, Professor of Biophysical Chemistry, University of Toronto